Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder. For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).
Dr. Goodman is a psychiatrist and scientist entrepreneur. Dr. Goodman was co-founder and CEO of PsychoGenics, a leading preclinical neuropharmacology company that combines its in vivo behavioral expertise with robotics, computer vision, and bio/cheminformatics to evaluate drug candidates for utility across the spectrum of neuropsychiatric disease indications. Using its unique technology platform, PsychoGenics identifies new therapeutic potentials for novel, discontinued and early stage compounds. Dr. Goodman was also co-founder and President of Resolvyx Pharmaceuticals, a biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases. Dr. Goodman's ongoing research interests span a broad spectrum, from the design and development of novel small molecule compounds for neuropsychiatric and inflammatory diseases to the repurposing of existing drugs for new neuropsychiatric indications. In addition to his scientific interests, Dr. Goodman is a practicing physician with a private psychiatry and psychopharmacology practice in New York and Greenwich, CT, where he treats patients with cognitive, mood, and anxiety disorders. Dr. Goodman also maintains an academic appointment as a clinical assistant professor in the Psychiatry Department at Cornell University Medical College, where he teaches medical students, residents and fellows.
He is a graduate of Yale College, Cambridge University, which he attended as a Churchill Fellow, Harvard Medical School, and Columbia Business School.
Dr. Harris serves as Medical Director for Rho, a leading clinical research organization. Prior to joining Rho, Dr. Harris practiced psychiatry with Weisler and Associates in Raleigh, NC. Dr. Harris served as Chief Medical Officer (CMO) at Tonix from July, 2009 until September, 2010. Prior to Tonix, Dr Harris served as CMO of Validus Pharmaceuticals where he was responsible for drug safety, clinical research and development, regulatory affairs, medical affairs and compliance for several marketed products. Dr. Harris has more than a decade of experience in drug development at Jazz Pharmaceuticals, GSK, Vela Pharmaceuticals, Cephalon and Merck. Dr. Harris served as CMO of Vela. His experience includes several international phase 3 programs in schizophrenia, depression and fibromyalgia, as well as phase 1, phase 2 and preclinical research in various CNS-related therapeutic areas. Prior to joining the industry, Dr. Harris served as Chief of the Geriatric Psychopharmacology Program at the National Institute of Mental Health. While at NIMH, he contributed to several major public health initiatives in mental health research including the Surgeon General's Report on Mental Health, DSM-IV-TR and the STAR*D study of treatment-resistant depression. He also served as scientific liaison to the Neuropharmacology Division of the FDA.
Dr. Harris received his MD and PhD from the University of Pittsburgh, and his psychiatric training at Yale University. After completing his clinical training, he served as Senior Staff Fellow at the National Institute on Aging, where his research focused on the molecular biology of Alzheimer's disease.
Dr. Iglehart is an internist and rheumatologist in solo private practice in Baltimore, MD and Assistant Professor, part-time in rheumatology at Johns Hopkins University School of Medicine. Dr. Iglehart is the inventor of Tonix's patented technology using very low dose (VLD)-cyclobenzaprine at bedtime to treat fibromyalgia. Dr. Iglehart is former President of the Johns Hopkins Alumni Association and in that capacity served on the Johns Hopkins University Board of Trustees under Chairman Michael Bloomberg for four years. In private practice for over 22 years, he spends more time with fewer patients, and still makes neighborhood house-calls. Dr. Iglehart's discovery of VLD-cyclobenzaprine's effects was motivated by his appreciation of the importance of sleep quality in both his general medical and rheumatologic patients.
Dr. Iglehart graduated Princeton University cum laude in 1979 and earned his M.D. at the Johns Hopkins University School of Medicine in 1983. He completed his residency in internal medicine and fellowship in rheumatology at Johns Hopkins.
Harvey Moldofsky is the President and Medical Director of the Sleep Disorders Clinic of the Center for Sleep and Chronobiology and President of the Toronto Psychiatric Research Foundation.He is an honorary member of the University Health Network Department of Psychiatry and consults for several Toronto hospitals and government agencies. Dr. Moldofsky has devoted his career to studying sleep physiology and biologic rhythm. He is renowned for work in fibromyalgia (FM) and particularly the relationships between chronic musculoskeletal pain, fatigue and non-restorative sleep. In 2001, Dr. Moldofsky was principal investigator of a study that tested the effect of bedtime administration of very low dose cyclobenzaprine on symptoms in FM patients, which is the proof-of-principle study for Tonix's Tonmya. Dr. Moldofsky was formerly Professor of Psychiatry and Medicine and is currently Professor Emeritus of the Faculty of Medicine and Member Emeritus, Institute of Medical Science, School of Graduate Studies at the University of Toronto. From 1993-2000 he served as founding Director of the University of Toronto's Center for Sleep and Chronobiology, and from 1998-2003 he was a medical assessor for the Workplace Safety and Insurance Appeals Tribunal of Ontario. Dr. Moldofsky has been the recipient of many local, national and international awards, including the regional award of the Royal College of Physicians and Surgeons of Canada for his contributions as a medical educator. In 1989, The Dr. Harvey Moldofsky Scholarship for Psychiatric/Neuroscience Research was formed in his honor. It is awarded annually to a medical student at the University of Toronto.
Dr. Moldofsky earned his MD from the University of Toronto and was engaged in postgraduate training in Vancouver, Toronto, London and San Francisco. He is a Distinguished Life Fellow of the American Psychiatric Association.